8-K: Iridex Reports Strong Q4 & Full Year 2025 Preliminary Results

Iridex Corporation announced preliminary unaudited operational and financial results for Q4 and full year 2025, showing continued revenue growth and positive cash flow.

Summary

• Q4 2025 total revenue is expected to be between $14.6 million and $14.8 million, representing year-over-year growth of 15% to 17% compared to $12.7 million in the prior year quarter.
• Achieved positive cash flow in the fourth quarter of 2025.
• Sold 15,800 Cyclo G6 probes in Q4 2025, an increase from 13,300 in the prior year quarter.
• Sold 44 Cyclo G6 Glaucoma Laser Systems in Q4 2025, compared to 47 in the prior year quarter.
• Full year 2025 total revenue is expected to be between $52.5 million and $52.7 million, representing year-over-year growth of 8% compared to $48.7 million in 2024.
• Expects to achieve positive adjusted EBITDA for the full year 2025.
• Sold 57,700 Cyclo G6 probes for the full year 2025, an increase from 55,400 in the prior year.
• Sold 133 Cyclo G6 Glaucoma Laser Systems for the full year 2025, an increase from 125 in the prior year.
• Achieved a fifth consecutive quarter of year-over-year revenue growth.
• Reduced operating expenses and improved adjusted EBITDA through focused cost reductions, gross margin expansion, and improved commercial efficiency.

Sentiment

Score: 8

Explanation: The company reported strong preliminary financial results with significant revenue growth, positive cash flow, and expected positive adjusted EBITDA, indicating successful operational execution and financial strengthening despite a slight dip in Q4 system sales.

Positives

• Achieved a fifth consecutive quarter of year-over-year revenue growth.
• Q4 2025 total revenue expected to grow 15% to 17% year-over-year, reaching $14.6 million to $14.8 million.
• Full year 2025 total revenue expected to grow 8% year-over-year, reaching $52.5 million to $52.7 million.
• Achieved positive cash flow in Q4 2025.
• Expects to achieve positive adjusted EBITDA for full year 2025.
• Increased Cyclo G6 probe sales in Q4 2025 to 15,800 from 13,300 in the prior year quarter.
• Increased Cyclo G6 probe sales for full year 2025 to 57,700 from 55,400 in the prior year.
• Increased Cyclo G6 Glaucoma Laser Systems sales for full year 2025 to 133 from 125 in the prior year.
• Strengthened financial position through focused cost reductions, gross margin expansion, and improved commercial efficiency.

Negatives

• Q4 2025 sales of Cyclo G6 Glaucoma Laser Systems decreased to 44 from 47 in the prior year quarter.

Risks

• Preliminary results are unaudited and subject to the completion of year-end financial reporting processes, further internal review, potential adjustments, and audit by external auditors.
• Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those described due to a number of factors.

Future Outlook

The company anticipates continued revenue growth, operational efficiencies, and positive cash flow, building on its strengthened financial position from focused cost reductions, gross margin expansion, and improved commercial efficiency.

Management Comments

• "In 2025, we strengthened our financial position through focused cost reductions, gross margin expansion, and improved commercial efficiency, and increased probe sales."
• "When we set and communicated our goals for 2025, we were clear about what we intended to accomplish—and in 2025 we delivered."
• "The actions we took drove a fifth consecutive quarter of year-over-year revenue growth, reduced operating expenses, and improved adjusted EBITDA."
• "We achieved positive cash flow in the fourth quarter of 2025, and we expect to achieve positive adjusted EBITDA for the full year 2025."

Industry Context

The announcement highlights Iridex's position as a worldwide leader in laser-based medical systems for glaucoma and retinal diseases, suggesting continued demand for innovative treatments in ophthalmology. The growth in probe sales indicates increasing adoption and utilization of their Cyclo G6 systems within the market.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, positive cash flow, and expected positive adjusted EBITDA, indicating improved financial health and operational efficiency.
• Customers (Ophthalmologists/Clinics): Continued availability and increased sales of Cyclo G6 probes and systems suggest ongoing support for their treatment needs.
• Employees: Positive performance may lead to job security and potential growth opportunities.

Next Steps

• Completion of the company's year-end financial reporting processes.
• Further internal review and potential adjustments of preliminary results.
• Audit by the company's external auditors.

Key Dates

Recommendation

The preliminary results demonstrate robust financial performance with consistent revenue growth, achievement of positive cash flow, and expected positive adjusted EBITDA. These indicators suggest strong operational execution, effective cost management, and increasing market penetration for their core products, making the stock an attractive investment.

Keywords

Iridex, IRIX, Glaucoma, Retinal Diseases, Laser Systems, Medical Devices, Ophthalmology, Financial Results, Revenue Growth, EBITDA, Cash Flow, Cyclo G6